UroGen Pharma Ltd’s filing revealed that its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $67401.0 on Jun 10 ’24. In the deal valued at $13.08 per share,5,153 shares were sold. As a result of this transaction, Schoenberg Mark now holds 144,284 shares worth roughly $2.18 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Schoenberg Mark sold 12,000 shares, generating $168,600 in total proceeds. Upon selling the shares at $14.05, the Chief Medical Officer now owns 139,437 shares.
Before that, Smith Jason Drew sold 4,993 shares. UroGen Pharma Ltd shares valued at $78,590 were divested by the General Counsel at a price of $15.74 per share. As a result of the transaction, Smith Jason Drew now holds 18,824 shares, worth roughly $0.28 million.
Jefferies downgraded its UroGen Pharma Ltd [URGN] rating to a Hold from a a Buy in a research note published on February 08, 2023; the price target was decreased to $10 from $35. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in late April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering URGN and reiterated its “Buy” recommendation on April 16, 2020. H.C. Wainwright maintained its rating on April 13, 2020. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock fall -8.13% to $15.14. Over the last five days, the stock has lost -8.19%. UroGen Pharma Ltd shares have risen nearly 0.93% since the year began. Nevertheless, the stocks have risen 46.28% over the past one year. While a 52-week high of $24.13 was reached on 06/14/24, a 52-week low of $8.69 was recorded on 05/13/24. SMA at 50 days reached $14.38, while 200 days put it at $14.57. A total of 0.54 million shares were traded, compared to the trading of 1.8 million shares in the previous session.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 14.66, which if violated will result in even more drops to 14.18. On the upside, there is a resistance level at 16.02. A further resistance level may holdings at 16.90. The Relative Strength Index (RSI) on the 14-day chart is 48.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.51, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.90%. Stochastics%K at 44.73% indicates the stock is a holding.
The most recent change occurred on January 09, 2020 when National Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $37 price target.
